A group of International Experts dedicated to changing practices to reduce potential contamination risks from occupational exposure to hazardous drugs on healthcare professionals.
Follow CytoPrevent on Twitter!
WHAT’S NEW ON CYTOPREVENT?
Pesqué Raphaëlle, Peyrilles Elodie, Jourdan Nathalie, Albert Odile, Sessink Paul, Madelaine Isabelle, Levert Hélène.
Occupational exposure to cytotoxic drugs can lead to significant health problems. This study was designed to evaluate the risk of 5-fluorouracil (5-FU) contamination for nurses when disconnecting the infusion line of an elastomeric pump from a non-coring needle, by comparing three configurations.
The handling of Hazardous medical drugs in a cancer treatment unit requires a specific approach in order to avoid unnecessary risks for the healthcare staff, and more particularly for the nurses. The measures to be taken concern both the preparation and administration phases.
The trilogue process with the European Council, Parliament and Commission under the Portuguese Presidency concludes today and there has been no discussion at all on the important legislative changes to the Carcinogens and Mutagens Directive (CMD), passed by the European Parliament to protect workers from cancer and reproductive problems at work.
Highlighting where the risks for healthcare workers when administering Chemotherapy are.
CytoPrevent* Advisory Board proposals to update the CMD.
While the European Commission has just started the Trilog process to amend the Carcinogen and Mutagen Directive (CMD) , CytoPrevent Advisory Board wishes to express some key concerns and formulates its expectations regarding the outcomes.
The need to use a more appropriate acronym for CSTDs for administration of cytotoxic drugs.
Proposal for including in the amendment of Directive 2004/37/EC on the protection of workers from the risks related to exposure to carcinogens or mutagens at work, a specific name for closed system used for administration of chemotherapy.
To reinforce protection of workers from exposure to hazardous medicinal products, including cytotoxic medicinal products: an Independent Group to European Commission made a study with different proposals.
The CytoPrevent board strongly supports the European Parliament vote to include hazardous drugs and reprotoxics in the Carcinogens and Mutagens Directive (CMD) to guaranty a safer working environment for healthcare professionals.
Today, scientific experts from several countries announce the creation of CytoPrevent, a group dedicated to make proposals and recommendations to ensure that the highest protection measures become standard for healthcare workers handling, preparing or administering hazardous drugs.